




FIG. 1




FIG. 2B




FIG. 2A




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5

7/88






FIG. 6A

8/88

**FIG. 6B**





FIG. 6C






FIG. 7B

12/88




FIG. 7C




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A





FIG. 11B








FIG. 12B

21/88

Harnessing Fc Receptors



mRNA & LNP development



In Vivo Delivery




FIG. 12C




FIG. 13A




FIG. 13B






FIG. 13D




FIG. 13E




FIG. 14A




FIG. 14B

29/88





FIG. 14C



31/88




FIG. 14E

SUBSTITUTE SHEET (RULE 26)




FIG. 14F




FIG. 15A





FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16




FIG. 17A




FIG. 17B





FIG. 18A

FIG. 18B








FIG. 18D

44/88



Non-treated group show large tumors, with little to no cell infiltration. Necrotic core is present



2/4 treated have complete response by histology
No tumor detected

FIG. 19




FIG. 20A

FIG. 20B




FIG. 20C





FIG. 21

48/88

**FIG. 22**




FIG. 23





FIG. 24






FIG. 26




FIG. 27




FIG. 28

55/88




FIG. 29




FIG. 30




FIG. 31

58/88





FIG. 32



60/88





FIG. 34






FIG. 35




FIG. 36




FIG. 37

>15% of tumor myeloid cells express GP-75-FcαR Construct





FIG. 38




FIG. 3



Treatment ↓ tumor Tregs

FIG. 40






FIG. 42

69/88




FIG. 43




FIG. 44




FIG. 45




FIG. 46A




FIG. 46B




FIG. 47A




FIG. 47B




FIG. 48B

FIG. 48A




FIG. 49




FIG. 50




FIG. 51




FIG. 52




FIG. 53




FIG. 54




FIG. 55




FIG. 56




FIG. 57




FIG. 58




FIG. 59




FIG. 60




FIG. 61A

FIG. 61B




FIG. 62A




FIG. 62B